Exercise of options, PDMR transaction and TVR
("Renalytix" or the "Company")
Exercise of options, PDMR transaction and TVR
Included in the exercise of the Option Shares were options over 15,000 ordinary shares held by
Application has been made to the
Total voting rights
Following Admission, the Company will have 72,224,786 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 72,224,786.
For further information, please contact:
Renalytix plc |
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About KidneyIntelX
KidneyIntelX, is a first-of-kind, bioprognosticTM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Non-executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Exercise of options |
|||
c) |
Currency |
GBP |
|||
d)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
15,000 |
|
|
|
|
|
|
|
|
e)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
15,000 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
f)
|
Date of the transaction
|
|
|||
g)
|
Place of the transaction
|
Outside a trading venue |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Non-executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Sale of shares |
|||
c) |
Currency |
GBP |
|||
d)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
15,000 |
|
|
|
|
|
|
|
|
e)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
15,000 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
f)
|
Date of the transaction
|
|
|||
g)
|
Place of the transaction
|
|
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits of repeat testing with KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the